Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Setrusumab - Mereo BioPharma/Ultragenyx Pharmaceutical

Next Previous
Search
Drug Profile

Setrusumab - Mereo BioPharma/Ultragenyx Pharmaceutical

Alternative Names: Anti-sclerostin-monoclonal-antibody-Mereo; BPS-804; UX-143

Latest Information Update: 25 Nov 2024

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator MorphoSys; Novartis
  • Developer Mereo BioPharma; Novartis; Ultragenyx Pharmaceutical
  • Class Monoclonal antibodies
  • Mechanism of Action SOST protein inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Osteogenesis imperfecta
  • New Molecular Entity Yes
  • Available For Licensing Yes

Highest Development Phases

  • Phase III Osteogenesis imperfecta
  • Discontinued Hypophosphatasia; Postmenopausal osteoporosis

Most Recent Events

  • 25 Oct 2024 Phase-III clinical trials in Osteogenesis imperfecta (In children) in Japan (IV) (NCT05768854)
  • 07 Oct 2024 Setrusumab - Mereo BioPharma/Ultragenyx Pharmaceutical receives Breakthrough Therapy status for Osteogenesis imperfecta (In adults, In adolescents, In children) in USA
  • 11 Jun 2024 Updated efficacy data from a phase II/III Orbit trial in Osteogenesis imperfecta released by Ultragenyx and Mereo Biopharma

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top